PetMed Express, Inc. (PETS)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PetMed Express, Inc. (“PetMed” or “the Company”) (NASDAQ: PETS). Investors who purchased PetMed securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether PetMed has violated federal securities laws.
Investigation Details:
After the market closed on October 30, 2023, PetMed announced its Q2 2023 results, reporting, among other things, that dividends will be suspended for the Company to invest in projects and initiatives that can give better returns. Previously, PetMed has declared a $0.30 per share dividend for 10 consecutive quarters. In addition, the Company reported net sales of $71M, missing estimates by $5M. On this news, PetMed’s stock price fell $2.29 per share, or 24.94%, to close at $6.89 per share on October 31, 2023.
What’s Next?
If you are aware of any facts relating to this investigation or purchased PetMed securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]